Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy CRNX Stock  Free CRNX Stock Alerts

Crinetics Pharmaceuticals (CRNX) Financials

Crinetics Pharmaceuticals logo
$29.66 -0.12 (-0.40%)
Closing price 04:00 PM Eastern
Extended Trading
$29.66 0.00 (-0.02%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Crinetics Pharmaceuticals

Annual Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298
Consolidated Net Income / (Loss)		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298
Net Income / (Loss) Continuing Operations		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298
Total Pre-Tax Income 		-6.02 -9.16 -27 -50 -74 -108 -164 -215 -298
Total Operating Income		 -6.04 -9.13 -29 -54 -75 -108 -168 -223 -339
Total Gross Profit		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04
Total Revenue		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04
Operating Revenue		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 6.63 11 31 55 75 109 173 227 340
Selling, General & Admin Expense		 1.53 1.94 6.66 14 18 25 42 58 100
Research & Development Expense		 5.10 9.23 24 42 57 84 130 169 240
Total Other Income / (Expense), net		 0.03 -0.03 1.60 3.41 0.99 0.16 3.96 8.08 40
Interest & Investment Income		 0.04 0.03 1.75 3.46 0.99 0.16 3.31 8.24 41
Other Income / (Expense), net		 -0.00 -0.05 -0.15 -0.05 0.00 0.00 0.66 -0.16 -0.52
Basic Earnings per Share		 ($5.96) ($6.68) ($2.23) ($2.09) ($2.42) ($2.80) ($3.15) ($3.69) ($3.69)
Weighted Average Basic Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 51.98M 58.07M 80.78M
Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) ($2.09) ($2.42) ($2.80) ($3.15) ($3.69) ($3.69)
Weighted Average Diluted Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 51.98M 58.07M 80.78M
Weighted Average Basic & Diluted Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 53.91M 69.60M 93.05M

Quarterly Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -42 -45 -46 -51 -57 -61 -67 -74 -75 -83
Consolidated Net Income / (Loss)		 -42 -45 -46 -51 -57 -60 -67 -74 -77 -81
Net Income / (Loss) Continuing Operations		 -42 -45 -46 -51 -57 -60 -67 -74 -77 -81
Total Pre-Tax Income 		-42 -45 -46 -51 -57 -60 -67 -74 -77 -81
Total Operating Income		 -43 -48 -48 -53 -59 -63 -74 -83 -88 -95
Total Operating Expenses		 44 48 51 54 59 63 74 83 88 95
Selling, General & Admin Expense		 12 11 12 13 15 17 21 25 26 28
Research & Development Expense		 32 37 38 41 44 46 53 58 62 67
Total Other Income / (Expense), net		 1.53 2.57 1.98 2.02 1.52 2.56 7.07 8.73 11 14
Interest & Investment Income		 1.50 1.90 2.04 2.11 1.57 2.52 6.85 8.74 11 14
Basic Earnings per Share		 ($0.78) ($0.83) ($0.85) ($0.94) ($1.01) ($0.89) ($0.93) ($0.94) ($0.96) ($0.86)
Weighted Average Basic Shares Outstanding		 53.77M 51.98M 53.91M 54.28M 56.81M 58.07M 72.29M 79.01M 80.09M 80.78M
Diluted Earnings per Share		 ($0.78) ($0.83) ($0.85) ($0.94) ($1.01) ($0.89) ($0.93) ($0.94) ($0.96) ($0.86)
Weighted Average Diluted Shares Outstanding		 53.77M 51.98M 53.91M 54.28M 56.81M 58.07M 72.29M 79.01M 80.09M 80.78M
Weighted Average Basic & Diluted Shares Outstanding		 53.81M 53.91M 54.03M 54.69M 66.80M 69.60M 78.86M 80.04M 92.74M 93.05M

Annual Cash Flow Statements for Crinetics Pharmaceuticals

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -5.71 2.04 31 -4.65 53 108 -167 22 210
Net Cash From Operating Activities		 -5.47 -9.48 -19 -46 -62 -89 -115 -166 -226
Net Cash From Continuing Operating Activities		 -5.47 -9.48 -19 -46 -62 -89 -115 -166 -226
Net Income / (Loss) Continuing Operations		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298
Consolidated Net Income / (Loss)		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298
Depreciation Expense		 0.09 0.13 0.47 0.89 0.95 0.92 0.98 1.10 2.79
Amortization Expense		 - - -0.43 -1.23 -0.23 0.42 0.03 -6.27 -15
Non-Cash Adjustments To Reconcile Net Income		 0.27 0.27 2.32 6.52 11 17 29 45 73
Changes in Operating Assets and Liabilities, net		 0.19 -0.72 5.30 -2.13 0.38 1.10 19 8.04 12
Net Cash From Investing Activities		 -0.19 -0.30 -119 42 0.22 -56 -174 -200 -575
Net Cash From Continuing Investing Activities		 -0.19 -0.30 -119 42 0.22 -56 -174 -200 -575
Purchase of Property, Plant & Equipment		 -0.19 -0.30 -1.06 -0.49 -0.19 -0.44 -1.66 -4.69 -3.84
Purchase of Investments		 - - -118 -108 -136 -125 -330 -528 -1,147
Sale and/or Maturity of Investments		 - - 0.00 150 136 69 157 337 576
Net Cash From Financing Activities		 -0.05 12 170 0.07 115 253 122 389 1,010
Net Cash From Continuing Financing Activities		 -0.05 12 170 0.07 115 253 122 389 1,010
Repayment of Debt		 -0.05 -0.21 - - - 0.00 - - 0.00
Issuance of Common Equity		 - - 106 0.00 114 250 117 369 970
Other Financing Activities, net		 - 0.07 0.45 0.13 0.29 3.14 4.72 20 40

Quarterly Cash Flow Statements for Crinetics Pharmaceuticals

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -31 1.76 8.52 -1.64 103 -88 341 -94 15 -53
Net Cash From Operating Activities		 -38 -35 -41 -46 -41 -39 -53 -46 -63 -65
Net Cash From Continuing Operating Activities		 -39 -35 -41 -46 -41 -39 -53 -46 -63 -65
Net Income / (Loss) Continuing Operations		 -42 -45 -46 -51 -57 -60 -67 -74 -77 -81
Consolidated Net Income / (Loss)		 -42 -45 -46 -51 -57 -60 -67 -74 -77 -81
Depreciation Expense		 0.25 0.28 0.28 0.28 0.27 0.26 0.47 0.75 0.77 0.79
Amortization Expense		 -0.13 -0.35 -0.53 -0.91 -1.25 -3.58 -3.85 -3.41 -3.51 -4.16
Non-Cash Adjustments To Reconcile Net Income		 7.51 7.49 6.21 10 12 17 15 20 19 20
Changes in Operating Assets and Liabilities, net		 -4.21 2.37 -0.69 -4.42 4.85 8.30 2.69 11 -2.15 -0.31
Net Cash From Investing Activities		 6.82 37 49 31 -193 -87 0.31 -54 21 -542
Net Cash From Continuing Investing Activities		 6.82 37 49 31 -193 -87 0.31 -54 21 -542
Purchase of Property, Plant & Equipment		 -0.68 -0.27 -0.02 -0.24 -3.50 -0.94 -1.33 -0.96 -0.53 -1.03
Purchase of Investments		 -49 -34 -23 -59 -278 -168 -100 -192 -130 -725
Sale and/or Maturity of Investments		 56 71 71 91 88 87 101 139 151 184
Net Cash From Financing Activities		 1.08 0.12 0.48 13 338 38 394 5.50 57 554
Net Cash From Continuing Financing Activities		 1.08 0.12 0.48 13 338 38 394 5.50 57 554
Issuance of Common Equity		 -0.01 - 0.00 11 329 29 383 -4.31 47 544
Other Financing Activities, net		 1.09 0.12 0.48 1.35 8.92 9.17 10 9.81 11 9.54

Annual Balance Sheets for Crinetics Pharmaceuticals

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2019 2020 2021 2022 2023 2024
Total Assets		 16 130 183 351 352 635 1,435
Total Current Assets		 15 123 177 345 345 574 1,375
Cash & Equivalents		 14 40 93 201 33 55 265
Restricted Cash		 - - - - - 0.00 0.50
Short-Term Investments		 - 78 78 133 302 504 1,090
Prepaid Expenses		 0.97 4.95 6.61 11 11 16 21
Plant, Property, & Equipment, net		 0.40 3.95 3.18 2.83 3.50 11 12
Total Noncurrent Assets		 0.03 3.09 2.77 3.47 3.49 50 47
Long-Term Investments		 - - - 1.01 0.00 0.47 0.00
Other Noncurrent Operating Assets		 0.03 3.09 2.77 2.46 3.49 50 47
Total Liabilities & Shareholders' Equity		 16 130 183 351 352 635 1,435
Total Liabilities		 0.92 13 15 19 36 96 110
Total Current Liabilities		 0.90 8.34 10 16 28 44 60
Accounts Payable		 0.40 5.50 5.59 8.47 15 23 21
Accrued Expenses		 0.18 2.12 4.07 6.59 9.08 15 29
Current Deferred Revenue		 - - - 0.00 2.24 2.06 2.18
Other Current Liabilities		 - 0.72 0.84 0.94 1.05 4.17 7.15
Total Noncurrent Liabilities		 0.02 4.90 4.04 3.08 8.13 52 50
Noncurrent Deferred Revenue		 0.02 - - 0.00 6.10 4.75 4.70
Other Noncurrent Operating Liabilities		 - 4.85 4.01 3.07 2.02 48 45
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -15 117 169 332 316 539 1,325
Total Preferred & Common Equity		 -15 117 169 332 316 539 1,325
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -15 117 169 332 316 539 1,325
Common Stock		 1.24 211 337 608 759 1,192 2,276
Retained Earnings		 -16 -94 -168 -275 -439 -654 -952
Accumulated Other Comprehensive Income / (Loss)		 - 0.15 0.03 -0.38 -3.93 0.98 0.96

Quarterly Balance Sheets for Crinetics Pharmaceuticals

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 385 314 293 642 978 936 937
Total Current Assets		 378 305 285 576 917 875 878
Cash & Equivalents		 31 41 40 143 396 302 317
Short-Term Investments		 337 255 225 412 505 561 545
Prepaid Expenses		 9.96 9.28 20 21 16 12 15
Plant, Property, & Equipment, net		 3.56 3.27 3.22 9.76 12 12 12
Total Noncurrent Assets		 2.99 5.34 5.22 56 49 49 48
Long-Term Investments		 0.00 - - 4.67 0.00 0.00 0.00
Other Noncurrent Operating Assets		 2.99 5.34 5.22 51 49 49 48
Total Liabilities & Shareholders' Equity		 385 314 293 642 978 936 937
Total Liabilities		 34 34 39 94 103 105 104
Total Current Liabilities		 25 26 33 40 52 54 54
Accounts Payable		 13 16 21 22 29 24 18
Accrued Expenses		 7.72 6.83 8.60 13 15 20 26
Current Deferred Revenue		 2.32 2.12 2.08 1.66 2.46 2.56 1.69
Other Current Liabilities		 1.02 1.08 1.11 3.99 5.79 7.45 7.41
Total Noncurrent Liabilities		 8.95 7.36 6.53 53 51 50 51
Noncurrent Deferred Revenue		 6.65 5.62 5.07 5.14 4.74 4.32 5.20
Other Noncurrent Operating Liabilities		 2.30 1.74 1.46 48 47 46 46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 351 280 254 548 875 831 833
Total Preferred & Common Equity		 351 280 254 548 875 831 833
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 351 280 254 548 875 831 833
Common Stock		 751 768 792 1,142 1,595 1,626 1,702
Retained Earnings		 -394 -485 -536 -594 -721 -795 -872
Accumulated Other Comprehensive Income / (Loss)		 -5.01 -2.51 -1.71 -0.87 0.15 -0.19 2.04

Annual Metrics and Ratios for Crinetics Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 247.20% 18.73% -50.86% -88.10% 659.15% 339.42% -15.28% -74.11%
EBITDA Growth		 0.00% -51.97% -218.61% -88.11% -36.90% -43.28% -56.27% -37.14% -54.22%
EBIT Growth		 0.00% -51.78% -214.58% -86.68% -39.11% -43.69% -55.27% -33.21% -52.34%
NOPAT Growth		 0.00% -51.01% -214.56% -87.50% -39.24% -43.69% -55.88% -32.60% -52.22%
Net Income Growth		 0.00% -52.13% -196.11% -85.96% -46.39% -45.83% -52.28% -30.88% -39.10%
EPS Growth		 0.00% -12.08% 66.62% 6.28% -15.79% -15.70% -12.50% -17.14% 0.00%
Operating Cash Flow Growth		 0.00% -73.35% -105.29% -138.35% -33.73% -42.82% -30.05% -44.36% -35.88%
Free Cash Flow Firm Growth		 0.00% 0.00% -185.26% -85.76% -42.08% -44.09% -37.03% -50.70% -47.63%
Invested Capital Growth		 0.00% 0.00% -100.00% 0.00% -56.50% -41.41% -552.61% -10.07% -49.43%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 1,418.31% -23.40% -15.01% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -6,361.43% -17,009.34% -9.21% -11.02% -8.84% -10.24%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.23% -10.59% -7.35% -10.63%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.23% -11.02% -7.28% -10.46%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.29% -9.48% -7.57% -7.38%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -2.19% -5.00% -1.65% 0.81%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -21.92% -19.10% -4.18% -8.53% -11.96% -2.03% -13.09%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -1,931.36% -8.26% -15.35% -2.21% -15.63%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 41.72% -592.71% -1,146.42% -6.52% -72.07% -0.26%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,010.70% -442.40% -1,187.19% -4,545.18% -52,276.06% -9,866.23% -3,508.72% -5,680.04% -33,832.44%
Operating Margin		 -1,026.15% -446.31% -1,182.45% -4,512.32% -52,783.80% -9,990.91% -3,544.06% -5,547.17% -32,613.47%
EBIT Margin		 -1,026.32% -448.66% -1,188.76% -4,516.51% -52,783.80% -9,990.91% -3,530.19% -5,551.13% -32,663.43%
Profit (Net Income) Margin		 -1,021.90% -447.78% -1,116.76% -4,226.49% -51,980.28% -9,985.25% -3,460.38% -5,345.85% -28,720.69%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 99.80% 100.09% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.57% 99.80% 93.94% 93.58% 98.68% 99.85% 98.02% 96.30% 87.93%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -2,629.18% -8,270.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -2,590.17% -8,171.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 2,504.41% 7,900.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -124.77% -369.46% -86.09% -51.61% -42.98% -50.57% -50.16% -32.02%
Cash Return on Invested Capital (CROIC)		 0.00% -2,829.18% -8,070.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -58.82% -370.09% -82.66% -47.77% -40.30% -47.56% -45.12% -32.79%
Return on Assets (ROA)		 0.00% -58.71% -347.67% -77.35% -47.04% -40.28% -46.62% -43.45% -28.83%
Return on Common Equity (ROCE)		 0.00% 127.70% 378.12% -86.09% -51.61% -42.98% -50.57% -50.16% -32.02%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 60.96% 0.00% -43.04% -43.70% -32.43% -51.82% -39.79% -22.52%
Net Operating Profit after Tax (NOPAT)		 -4.23 -6.39 -20 -38 -52 -75 -118 -156 -237
NOPAT Margin		 -718.30% -312.42% -827.72% -3,158.63% -36,948.66% -6,993.64% -2,480.84% -3,883.02% -22,829.43%
Net Nonoperating Expense Percent (NNEP)		 0.00% -39.01% -98.90% -21.52% -14.76% -12.76% -13.87% -13.14% -6.40%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -37.15% -28.90% -17.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 260.27% 94.82% 274.26% 1,133.19% 12,694.37% 2,275.05% 894.95% 1,447.65% 9,599.33%
R&D to Revenue		 865.87% 451.49% 1,008.20% 3,479.13% 40,139.44% 7,815.86% 2,749.10% 4,199.53% 23,114.15%
Operating Expenses to Revenue		 1,126.15% 546.31% 1,282.45% 4,612.32% 52,728.17% 10,099.81% 3,644.06% 5,647.17% 32,713.47%
Earnings before Interest and Taxes (EBIT)		 -6.05 -9.18 -29 -54 -75 -108 -167 -223 -339
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.95 -9.05 -29 -54 -74 -106 -166 -228 -352
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 5.19 2.75 4.07 3.11 3.56 2.08
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 5.19 2.75 4.07 3.11 3.56 2.08
Price to Revenue (P/Rev)		 173.17 49.88 296.90 509.42 3,271.37 1,251.83 207.88 477.97 2,652.90
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 241.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 57.46 296.90 410.18 2,067.99 941.33 137.28 338.66 1,349.17
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.97 -0.97 -1.01 -1.01 -1.01 -1.03 -1.04 -1.03
Leverage Ratio		 0.00 1.06 1.06 1.11 1.10 1.07 1.08 1.15 1.11
Compound Leverage Factor		 0.00 1.06 1.00 1.04 1.08 1.07 1.06 1.11 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 202.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -102.34% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 64.35 0.00 26.24 17.65 41.47 14.26 10.37 14.46
Noncontrolling Interest Sharing Ratio		 0.00% 202.34% 202.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 16.91 0.00 14.79 16.92 21.55 12.45 13.07 23.04
Quick Ratio		 0.00 15.82 0.00 14.20 16.29 20.86 12.06 12.71 22.69
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.87 -20 -36 -52 -75 -102 -154 -227
Operating Cash Flow to CapEx		 -2,877.89% -3,118.09% -1,837.49% -9,427.03% -33,347.85% -20,318.35% -6,956.82% -3,547.50% -5,878.51%
Free Cash Flow to Firm to Interest Expense		 0.00 -859.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -497.09 -1,184.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -514.36 -1,222.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.13 0.31 0.02 0.00 0.00 0.01 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 5.11 0.00 0.00 0.04 0.36 1.50 0.56 0.09
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.49 0.00 -1.25 -1.96 -2.77 -18 -20 -30
Invested Capital Turnover		 0.00 8.42 9.99 -1.90 -0.09 -0.46 -0.45 -0.21 -0.04
Increase / (Decrease) in Invested Capital		 0.00 0.49 -0.49 -1.25 -0.71 -0.81 -15 -1.82 -9.85
Enterprise Value (EV)		 0.00 118 721 489 294 1,015 650 1,359 1,402
Market Capitalization		 102 102 721 608 465 1,349 985 1,918 2,756
Book Value per Share		 $0.00 ($10.96) $0.00 $4.84 $5.13 $6.99 $5.88 $8.07 $14.29
Tangible Book Value per Share		 $0.00 ($10.96) $0.00 $4.84 $5.13 $6.99 $5.88 $8.07 $14.29
Total Capital		 0.00 15 0.00 117 169 332 316 539 1,325
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -14 0.00 -118 -171 -335 -334 -559 -1,355
Capital Expenditures (CapEx)		 0.19 0.30 1.06 0.49 0.19 0.44 1.66 4.69 3.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.08 0.00 -3.39 -3.88 -4.98 -17 -28 -39
Debt-free Net Working Capital (DFNWC)		 0.00 14 0.00 115 167 329 317 530 1,316
Net Working Capital (NWC)		 0.00 14 0.00 115 167 329 317 530 1,316
Net Nonoperating Expense (NNE)		 1.79 2.77 7.02 13 21 32 46 59 61
Net Nonoperating Obligations (NNO)		 0.00 -14 0.00 -118 -171 -335 -334 -559 -1,355
Total Depreciation and Amortization (D&A)		 0.09 0.13 0.04 -0.34 0.72 1.34 1.02 -5.17 -12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 3.72% 0.00% -284.41% -2,730.28% -462.15% -358.12% -706.30% -3,740.62%
Debt-free Net Working Capital to Revenue		 0.00% 697.70% 0.00% 9,639.48% 117,607.75% 30,493.97% 6,701.73% 13,212.33% 126,631.76%
Net Working Capital to Revenue		 0.00% 697.70% 0.00% 9,639.48% 117,607.75% 30,493.97% 6,701.73% 13,212.33% 126,631.76%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) ($3.15) ($3.69) ($3.69)
Adjusted Weighted Average Basic Shares Outstanding		 1.01M 1.37M 24.10M 0.00 33.03M 47.78B 51.98M 58.07M 80.78M
Adjusted Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) ($3.15) ($3.69) ($3.69)
Adjusted Weighted Average Diluted Shares Outstanding		 1.01M 1.37M 24.10M 0.00 33.03M 47.78B 51.98M 58.07M 80.78M
Adjusted Basic & Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.01M 1.37M 12.14M 0.00 30.45M 38.44M 53.91M 69.60M 93.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.23 -6.39 -20 -38 -52 -75 -118 -156 -237
Normalized NOPAT Margin		 -718.30% -312.42% -827.72% -3,158.63% -36,948.66% -6,993.64% -2,480.84% -3,883.02% -22,829.43%
Pre Tax Income Margin		 -1,021.90% -447.78% -1,116.76% -4,226.49% -52,085.92% -9,976.35% -3,460.38% -5,345.85% -28,720.69%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -549.55 -1,146.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -384.62 -798.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -566.82 -1,184.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -401.89 -836.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Crinetics Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -34.23% -14.44% 125.06% -24.45% 0.00% -76.11% -59.62% -100.00% 0.00%
EBITDA Growth		 -57.44% -56.32% -45.05% -25.99% -38.55% -38.53% -59.47% -59.08% -50.95% -48.71%
EBIT Growth		 -56.17% -53.96% -41.90% -23.33% -35.94% -31.76% -53.26% -55.97% -48.80% -51.21%
NOPAT Growth		 -56.27% -53.96% -41.83% -23.12% -35.72% -31.76% -53.26% -56.21% -48.87% -51.21%
Net Income Growth		 -50.53% -46.10% -32.83% -20.30% -37.05% -33.58% -45.52% -45.27% -33.71% -34.11%
EPS Growth		 -6.85% -22.06% -16.44% -16.05% -29.49% -7.23% -9.41% 0.00% 4.95% 3.37%
Operating Cash Flow Growth		 -49.88% -53.75% -200.66% -63.48% -7.43% -9.40% -29.81% 0.26% -51.97% -67.92%
Free Cash Flow Firm Growth		 31.91% 13.67% -325.66% -384.79% -254.77% -134.00% -19.38% 26.22% 7.18% -34.34%
Invested Capital Growth		 -6,511.32% -552.61% 5.71% 53.39% 31.87% -10.07% -64.82% -209.13% -156.46% -49.43%
Revenue Q/Q Growth		 4.33% 54.80% 277.86% -63.12% -64.98% 0.00% 0.00% -37.66% -100.00% 0.00%
EBITDA Q/Q Growth		 -1.58% -9.97% -1.26% -11.39% -11.70% -9.96% -16.55% -11.12% -6.00% -8.33%
EBIT Q/Q Growth		 -0.88% -9.51% -0.89% -10.65% -11.20% -6.15% -17.35% -12.60% -6.08% -7.87%
NOPAT Q/Q Growth		 -0.95% -9.44% -0.89% -10.46% -11.29% -6.24% -17.35% -12.59% -6.06% -7.91%
Net Income Q/Q Growth		 1.06% -7.31% -2.23% -10.84% -12.71% -4.59% -11.37% -10.65% -3.74% -4.90%
EPS Q/Q Growth		 3.70% -6.41% -2.41% -10.59% -7.45% 11.88% -4.49% -1.08% -2.13% 10.42%
Operating Cash Flow Q/Q Growth		 -37.54% 8.50% -15.65% -12.32% 9.61% 6.83% -37.23% 13.70% -37.72% -2.95%
Free Cash Flow Firm Q/Q Growth		 -30.16% -36.48% -92.27% -41.93% 4.75% 9.98% 1.91% 12.28% -19.84% -30.29%
Invested Capital Q/Q Growth		 23.95% -6.52% 12.74% 34.06% -11.17% -72.07% -30.67% -23.67% 7.77% -0.26%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -9,456.11% -6,717.49% -1,800.11% -5,436.94% -17,341.91% 0.00% -12,015.94% -21,416.29% 0.00% 0.00%
Operating Margin		 -9,487.77% -6,707.48% -1,790.89% -5,363.87% -17,045.38% 0.00% -11,488.91% -20,747.62% 0.00% 0.00%
EBIT Margin		 -9,481.44% -6,707.48% -1,790.89% -5,373.08% -17,060.69% 0.00% -11,488.91% -20,750.88% 0.00% 0.00%
Profit (Net Income) Margin		 -9,153.93% -6,345.70% -1,716.87% -5,159.82% -16,606.36% 0.00% -10,457.81% -18,560.15% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.89% 100.12% 100.00% 100.00% 99.91% 100.38% 100.00% 100.00% 99.69%
Interest Burden Percent		 96.55% 94.71% 95.75% 96.03% 97.34% 96.00% 90.68% 89.44% 87.47% 85.33%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.95% -50.57% -60.09% -57.44% -44.36% -50.16% -40.76% -47.66% -40.26% -32.02%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -197.34% -90.37% -23.71% -72.65% -156.97% 0.00% -35.10% -46.78% 0.00% 0.00%
Return on Assets (ROA)		 -190.52% -85.49% -22.73% -69.77% -152.79% 0.00% -31.95% -41.84% 0.00% 0.00%
Return on Common Equity (ROCE)		 -54.95% -50.57% -60.09% -57.44% -44.36% -50.16% -40.76% -47.66% -40.26% -32.02%
Return on Equity Simple (ROE_SIMPLE)		 -42.61% 0.00% -62.53% -72.36% -36.41% 0.00% -26.91% -31.12% -33.36% 0.00%
Net Operating Profit after Tax (NOPAT)		 -30 -33 -34 -37 -41 -44 -51 -58 -61 -66
NOPAT Margin		 -6,641.44% -4,695.23% -1,253.62% -3,754.71% -11,931.76% 0.00% -8,042.23% -14,523.33% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.10% -3.50% -4.03% -4.13% -3.49% -3.63% -2.58% -2.86% -2.16% -1.49%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.52% - - - -8.14% - - - -5.01%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,603.71% 1,590.13% 454.98% 1,350.51% 4,475.14% 0.00% 3,254.38% 6,225.06% 0.00% 0.00%
R&D to Revenue		 6,984.06% 5,217.35% 1,435.91% 4,113.36% 12,670.23% 0.00% 8,334.53% 14,622.56% 0.00% 0.00%
Operating Expenses to Revenue		 9,587.77% 6,807.48% 1,890.89% 5,463.87% 17,145.38% 0.00% 11,588.91% 20,847.62% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -43 -48 -48 -53 -59 -63 -74 -83 -88 -95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -43 -48 -48 -54 -60 -66 -77 -85 -91 -98
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.00 3.11 3.09 3.82 2.93 3.56 2.88 2.91 3.31 2.08
Price to Tangible Book Value (P/TBV)		 3.00 3.11 3.09 3.82 2.93 3.56 2.88 2.91 3.31 2.08
Price to Revenue (P/Rev)		 170.72 207.88 202.05 200.96 339.53 477.97 1,278.36 1,743.38 2,651.34 2,652.90
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 111.15 137.28 132.94 146.24 221.08 338.66 821.94 1,120.31 1,821.05 1,349.17
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.03 -1.06 -1.05 -1.03 -1.04 -1.04 -1.04 -1.03 -1.03
Leverage Ratio		 1.09 1.08 1.11 1.12 1.14 1.15 1.12 1.13 1.14 1.11
Compound Leverage Factor		 1.05 1.03 1.06 1.07 1.11 1.11 1.01 1.01 1.00 0.95
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 18.22 15.39 13.84 12.78 9.67 11.20 14.45 13.40 15.28 15.02
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 15.41 12.45 11.60 8.73 14.23 13.07 17.72 16.09 16.38 23.04
Quick Ratio		 15.00 12.06 11.25 8.11 13.71 12.71 17.40 15.87 16.11 22.69
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 -18 -35 -49 -47 -42 -41 -36 -43 -56
Operating Cash Flow to CapEx		 -5,642.08% -12,849.27% -254,487.50% -19,297.47% -1,181.11% -4,119.25% -3,968.17% -4,776.65% -11,898.30% -6,285.13%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.91 1.50 1.44 1.52 0.71 0.56 0.26 0.18 0.10 0.09
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -17 -18 -16 -10 -12 -20 -26 -32 -30 -30
Invested Capital Turnover		 -0.74 -0.45 -0.26 -0.30 -0.33 -0.21 -0.09 -0.07 -0.05 -0.04
Increase / (Decrease) in Invested Capital		 -17 -15 0.96 12 5.41 -1.82 -10 -22 -18 -9.85
Enterprise Value (EV)		 687 650 570 707 1,044 1,359 1,623 1,552 1,892 1,402
Market Capitalization		 1,056 985 866 971 1,603 1,918 2,523 2,415 2,755 2,756
Book Value per Share		 $6.54 $5.88 $5.20 $4.70 $10.02 $8.07 $12.57 $10.53 $10.41 $14.29
Tangible Book Value per Share		 $6.54 $5.88 $5.20 $4.70 $10.02 $8.07 $12.57 $10.53 $10.41 $14.29
Total Capital		 351 316 280 254 548 539 875 831 833 1,325
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -368 -334 -296 -265 -559 -559 -901 -863 -863 -1,355
Capital Expenditures (CapEx)		 0.68 0.27 0.02 0.24 3.50 0.94 1.33 0.96 0.53 1.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -17 -17 -12 -19 -28 -36 -43 -39 -39
Debt-free Net Working Capital (DFNWC)		 354 317 279 252 535 530 865 820 824 1,316
Net Working Capital (NWC)		 354 317 279 252 535 530 865 820 824 1,316
Net Nonoperating Expense (NNE)		 12 12 12 14 16 16 15 16 15 14
Net Nonoperating Obligations (NNO)		 -368 -334 -296 -265 -559 -559 -901 -863 -863 -1,355
Total Depreciation and Amortization (D&A)		 0.12 -0.07 -0.25 -0.63 -0.97 -3.32 -3.37 -2.66 -2.74 -3.38
Debt-free, Cash-free Net Working Capital to Revenue		 -236.01% -358.12% -397.67% -255.05% -409.91% -706.30% -1,798.38% -3,072.49% -3,719.25% -3,740.62%
Debt-free Net Working Capital to Revenue		 5,720.68% 6,701.73% 6,513.00% 5,217.21% 11,336.23% 13,212.33% 43,843.01% 59,234.58% 79,309.43% 126,631.76%
Net Working Capital to Revenue		 5,720.68% 6,701.73% 6,513.00% 5,217.21% 11,336.23% 13,212.33% 43,843.01% 59,234.58% 79,309.43% 126,631.76%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.78) ($0.83) ($0.85) ($0.94) ($1.01) ($0.89) ($0.93) ($0.94) ($0.96) ($0.86)
Adjusted Weighted Average Basic Shares Outstanding		 53.77M 51.98M 53.91M 54.28M 56.81M 58.07M 72.29M 79.01M 80.09M 80.78M
Adjusted Diluted Earnings per Share		 ($0.78) ($0.83) ($0.85) ($0.94) ($1.01) ($0.89) ($0.93) ($0.94) ($0.96) ($0.86)
Adjusted Weighted Average Diluted Shares Outstanding		 53.77M 51.98M 53.91M 54.28M 56.81M 58.07M 72.29M 79.01M 80.09M 80.78M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 53.81M 53.91M 54.03M 54.69M 66.80M 69.60M 78.86M 80.04M 92.74M 93.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -33 -34 -37 -41 -44 -51 -58 -61 -66
Normalized NOPAT Margin		 -6,641.44% -4,695.23% -1,253.62% -3,754.71% -11,931.76% 0.00% -8,042.23% -14,523.33% 0.00% 0.00%
Pre Tax Income Margin		 -9,153.93% -6,352.75% -1,714.82% -5,159.82% -16,606.36% 0.00% -10,418.59% -18,560.15% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Crinetics Pharmaceuticals' Financials

When does Crinetics Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Crinetics Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Crinetics Pharmaceuticals' net income changed over the last 8 years?

Crinetics Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$298.41 million in 2024, rising from -$6.02 million in 2016. The previous period was -$214.53 million in 2023.

What is Crinetics Pharmaceuticals's operating income?
Crinetics Pharmaceuticals's total operating income in 2024 was -$338.85 million, based on the following breakdown:
  • Total Gross Profit: $1.04 million
  • Total Operating Expenses: $339.89 million
How has Crinetics Pharmaceuticals revenue changed over the last 8 years?

Over the last 8 years, Crinetics Pharmaceuticals' total revenue changed from $589 thousand in 2016 to $1.04 million in 2024, a change of 76.4%.

How much debt does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals' total liabilities were at $109.79 million at the end of 2024, a 14.1% increase from 2023, and a 11,833.4% increase since 2017.

How much cash does Crinetics Pharmaceuticals have?

In the past 6 years, Crinetics Pharmaceuticals' cash and equivalents has ranged from $14.19 million in 2017 to $264.55 million in 2024, and is currently $264.55 million as of their latest financial filing in 2024.

How has Crinetics Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Crinetics Pharmaceuticals' book value per share changed from 0.00 in 2016 to 14.29 in 2024, a change of 1,428.6%.

Remove Ads

Related Companies

This page (NASDAQ:CRNX) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...
Altimetry | Sponsored
Amazon Shocker
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...
Stansberry Research | Sponsored
Caught on Camera: Elon Musk’s “Area 51”
You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...
Brownstone Research | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored